Skip to main content

Table 2 Summary of the significant parameters for different malignant grades and molecular subtypes

From: Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization

  Emax (kPa) fmass (Hz) Dmax (mm) NV mvFD NB
Histologic type
 Benign (310)       
Fibroadenoma (109) 49.5 ± 33.8 143.0 ± 64.5 448.6 ± 262.8 5.9 ± 9.8 0.92 ± 0.43 2.8 ± 6.2
 Benign changes (77) 44.5 ± 38.6 146.4 ± 94.0 356.9 ± 291.6 2.9 ± 5.4 0.83 ± 0.38 1.2 ± 2.6
 Fibrocystic changes (30) 48.6 ± 31.9 171.1 ± 104.4 429.3 ± 282.6 4.4 ± 7.9 0.87 ± 0.43 1.7 ± 4.0
 Papilloma (28) 51.8 ± 39.2 186.7 ± 88.3 454.0 ± 273.3 3.4 ± 4.2 0.95 ± 0.28 1.3 ± 1.8
 PASH (22) 36.3 ± 28.3 139.8 ± 79.6 438.7 ± 247.5 3.1 ± 3.8 0.95 ± 0.27 1.0 ± 1.6
 Fat necrosis (18) 97.1 ± 70.6 203.5 ± 184.1 574.9 ± 106.2 3.9 ± 3.0 1.1 ± 0.11 1.5 ± 1.3
 Atypical (14) 51.2 ± 34.3 192.3 ± 105.3 303.4 ± 305.7 5.1 ± 9.9 0.75 ± 0.48 2.7 ± 5.6
 Duct ectasia (6) 45.9 ± 20.7 231.8 ± 86.7 501.0 ± 270.8 2.5 ± 2.1 0.95 ± 0.19 0.5 ± 0.5
 Adenoma (4) 47.9 ± 29.1 99.2 ± 56.2 655.4 ± 165.2 22 ± 22.7 1.28 ± 0.23 10.5 ± 13.0
 Others (2) 103.0 ± 95.8 243.9 ± 71.1 708.5 ± 238.7 10 ± 11.3 1.24 ± 0.25 7 ± 8.5
 p valuea .03 .02 .03 .003 .01 .06
Malignant (204)
 IDC (136) 161.6 ± 65.1 212.3 ± 124.9 640.9 ± 197.3 15.2 ± 15.9 1.19 ± 0.21 7.4 ± 9.2
 IMC with mixed ductal and lobular features (27) 174.7 ± 68.3 227.8 ± 139.1 593.0 ± 278.2 17.0 ± 18.4 1.16 ± 0.23 8.2 ± 10.1
 ILC (24) 168.8 ± 56.2 241.1 ± 128.9 567.6 ± 268.8 14.6 ± 25.0 1.14 ± 0.19 7.3 ± 14.6
 DCIS (15) 94.6 ± 74.5 253.3 ± 172.6 503.8 ± 291.7 7.3 ± 5.9 1.11 ± 0.23 3.7 ± 3.4
 Other (2) 154.1 ± 48.5 97.2 ± 90.6 811.4 ± 142.3 100 ± 76.4 1.50 ± 0.13 69 ± 46.7
 p valuea .55 .48 .22 .33 .21 .31
Histologic grade
 I (54) 139.1 ± 69.2 278.5 ± 117.1 553.6 ± 244.3 7.5 ± 8.3 1.10 ± 0.20 3.5 ± 4.4
 II (92) 168.0 ± 66.0 220.6 ± 140.7 617.7 ± 210.2 15.0 ± 16.3 1.18 ± 0.18 7.3 ± 9.2
 III (54) 165.8 ± 64.2 155.6 ± 90.8 673.9 ± 233.5 24.1 ± 28.6 1.24 ± 0.24 12.4 ± 18.3
 p valuea .05  < .001 .02  < .001  < .001  < .001
Molecular subtypes
 Luminal A (76) 155.7 ± 66.4 257.3 ± 120.5 577.0 ± 241.4 10.8 ± 14.2 1.13 ± 0.21 5.2 ± 8.0
 Luminal B (HER2-) (58) 176.4 ± 61.4 218.2 ± 139.0 625.5 ± 181.0 15.2 ± 15.7 1.18 ± 0.16 7.4 ± 9.3
 Luminal B (HER2 +) (21) 198.4 ± 49.8 136.2 ± 98.4 727.1 ± 155.5 28.6 ± 32.6 1.30 ± 0.13 14.5 ± 21.8
 HER2 + (4) 169.1 ± 31.5 95.5 ± 33.2 628.7 ± 149.6 15.8 ± 14.5 1.20 ± 0.18 7.3 ± 6.4
 TNBC (20) 131.6 ± 65.4 189.3 ± 85.6 543.2 ± 311.5 13.9 ± 16.3 1.11 ± 0.35 7.3 ± 10.8
 p valuea .005  < .001 .07 .002 .01 .02
  1. Numbers are mean ± standard deviation, numbers in parentheses are numbers of participants
  2. DCIS, ductal carcinoma in situ. IDC, invasive ductal carcinoma. ILC, invasive lobular carcinoma. IMC with mixed ductal and lobular features, invasive mammary carcinoma with mixed ductal and lobular features. PASH, pseudoangiomatous stromal hyperplasia. TNBC, triple negative breast cancer
  3. aKruskal-Wallis test